The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol

References 

1. Swyer GI, Little V. Clinical assessment of relative potency of progestagens. J Reprod Fertil. 1968;5(suppl):63–68
2. Spona J, Huber J. Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate. Gynecol Obstet Invest. 1987;23:184–193
   • MEDLINE
   • CrossRef
3. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47:583–590
   • Abstract
   • Full-Text PDF (437 KB)
   • CrossRef
4. In:  Seibel MM,  Blackwell RE editor. Ovulation induction. New York: Raven Press; 1994;p. 174
5. Stubblefield PG. Health benefits beyond contraception. Int J Fertil. 1994;39(suppl 3):132–138
6. Drife J. Benefits and risks of oral contraceptives. Adv Contracept. 1990;6(suppl):15–25
7. Anonymous . Combined oral contraceptives: a statement by the Committee on Safety of Drugs. BMJ. 1970;2:231–232
   • CrossRef
8. Jeffcoat TN. RCOG statement on oral contraceptives. BMJ. 1970;1:293
   • CrossRef
9. Apelo R, Veloso I. Clinical experience with ethinylestradiol and d-norgestrel as an oral contraceptive. Fertil Steril. 1975;26:283–288
   • MEDLINE
10. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB. Low-dose combination oral contraceptives: a controlled clinical study of three different norgestrel–ethinyl estradiol ratios. Fertil Steril. 1997;28:549–553
    • MEDLINE
11. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski G. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity. Eur J Contracept Reprod Health Care. 1996;1:245–256
    • MEDLINE
    • CrossRef
12. Spona J, Feichtinger W, Kindermann C, Wunsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinyl estradiol. Contraception. 1996;54:299–304
    • Abstract
    • Full-Text PDF (937 KB)
    • CrossRef
13. Bye PG. Analysis of a multicenter trial of a new low-dose oral contraceptive in Great Britain. Obstet General Scand Suppl. 1976;54:61–66
14. Sartoretto JN, Ortega-Recio JC. Clinical evaluation of a low dosage estrogen-progesterone association (100 μg of d-norgestrel and 20 μg of ethinyl estradiol). Rev Bras Clin Terap. 1974;3:399–404
15. Archer DF, Maheux R, DelConte A, O’Brien FB. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG) Contraception. 1997;55:139–144
    • Abstract
    • Full-Text PDF (636 KB)
    • CrossRef
16. Fitzgerald C, Feichtinger W, Spona J, Muller U, Williams C. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept. 1994;10:5–18
    • MEDLINE
    • CrossRef
17. Spona J, Elstein M, Feichtinger W, Sullivan H, Lüdicke F, Müller U, et al.  Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
    • Abstract
    • Full-Text PDF (1038 KB)
    • CrossRef
18. Teichmann AT, Brill K. A comparison of ovarian suppression and cycle control in women receiving monophasic oral contraceptives containing either 30 μg ethinylestradiol/75 μg gestodene or 20 μg ethinylestradiol/150 μg desogestrel. In: Symposium of Practical Issues in Oral Contraception; Dublin. June 1994;
19. Mishell DR. Noncontraceptive benefits of oral contraceptives. J Reprod Med. 1993;38(suppl 12):1021–1029
    • MEDLINE